First-line FOLFOXIRI/bevacizumab followed by retreatment with the same regimen upon progression improved PFS2 compared with sequential FOLFOX/bevacizumab followed by FOLFIRI/bevacizumab in unresectable mCRC.
In the phase III APACT trial, adding nab-paclitaxel to adjuvant gemcitabine did not significantly prolong DFS by independent review but improved OS in an interim analysis in resected pancreatic cancer.
In KEYNOTE-240, pembrolizumab showed nonsignificant improvement in PFS and OS compared with placebo as second-line therapy in advanced HCC.
Survival outcomes with trifluridine/tipiracil in patients aged ≥ 65 years or those with metastatic GEJ cancer were generally consistent with the overall patient population, and HRQoL outcomes were stable over time in the overall population.
Avapritinib is active in patients with advanced GIST harboring PDGFRA Exon 18 mutations and in those who received ≥ 3 lines of prior therapies.
Maintenance therapy with olaparib improved PFS vs placebo in patients with metastatic pancreatic cancer and germline BRCA mutations who had not progressed with platinum-based chemotherapy.